Commentary: Smokeless tobacco: Seeing the whole picture

International Journal of Epidemiology

Volumn 36, Issue 4, 2007, Pages 805-808

  McKee, Martin ^a   Gilmore, Anna ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

NICOTINE;

CARCINOGENICITY; CARDIOVASCULAR DISEASE; EUROPE; HEALTH HAZARD; HEALTH PROGRAM; HEALTH PROMOTION; HUMAN; LAW; MORTALITY; NOTE; PRIORITY JOURNAL; PUBLIC HEALTH; RISK FACTOR; SMOKELESS TOBACCO; SMOKING CESSATION; STRATEGIC PLANNING; TOBACCO INDUSTRY;

DRUG AND NARCOTIC CONTROL; EUROPEAN UNION; HUMANS; TOBACCO INDUSTRY; TOBACCO, SMOKELESS;

NICOTIANA TABACUM;

EID: 34548587171     PISSN: 03005771     EISSN: 14643685     Source Type: Journal    
DOI: 10.1093/ije/dym101     Document Type: Note

References (30)

1. Roper Organization. A Study of Public Attitudes toward Cigarette Smoking and the Tobacco Industry in 1978, Vol. 1. New York: Roper Organization, 1978.
2. European Union. COUNCIL DIRECTIVE 92/41/EEC of 15 May 1992 amending Directive 89/622/EEC on the approximation of the laws, regulations and administrative provisions of the Member States concerning the labelling of tobacco products. Official Journal of the European Communities 1992;L 158(11/06/1992):0030-33.
3. Scientific Committee on Emerging and Newly Identified Health Risks. Request for a scientific opinion on health effects of smokeless tobacco products. Brussels: European Commission, 2006.
4. Lee PN. Circulatory disease and smokeless tobacco in Western populations. A review of the evidence. Int J Epidemiol 2007; 36 789-804.
5. Glantz SA. The Cigarette Papers. Berkeley; London: University of California Press, 1996.
6. Gruning T, Gilmore AB, McKee M. Tobacco industry influence on science and scientists in Germany. Am J Public Health 2006;96:20-32.
7. Bates C, Fagerstrom K, Jarvis MJ, Kunze M, McNeill A, Ramstrom L. European Union policy on smokeless tobacco: A statement in favour of evidence based regulation for public health. Tob Control 2003; 12:360-67.
8. Rodu B, Stegmayr B, Nasic S, Asplund K. Impact of smokeless tobacco use on smoking in northern Sweden: J Intern Med 2002;252:398-404.
9. Scollo M. Recreational nicotine: Uncertain benefits and several major risks [commment]. Tob Control 2000;9:240-41.
10. WHO International Agency for Research on Cancer. IARC Monographs on the evaluation of carcinogenic risks to humans. Volume 85: Betel-quid and areca-nut chewing and some areca-nut-derived nitrosamines. Lyons. IARC, 2004.
11. Foulds J, Ramstrom L, Burke M, Fagerstrom K. Effect of smokeless tobacco (snus) on smoking and public health in Sweden. Tob Control 2003; 12:349-59.
12. Osterdahl BG, Jansson C, Paccou. A. Decreased levels of tobacco-specific N-nitrosamines in moist snuff on the Swedish market. J Agric Food Chem 2004;52:5085-88.
13. Gupta PC, Ray CS. Smokeless tobacco and health in India and South Asia. Respirology 2003;8:419-31.
14. Cogliano V, Straif K, Baan R, Grosse Y, Secretan B, El Ghissassi F. Smokeless tobacco and tobacco-related nitrosamines. Lancet Oncol 2004;5:708.
15. Boffetta P, Aagnes B, Weiderpass E, Andersen A. Smokeless tobacco use and risk of cancer of the pancreas and other organs. Int J Cancer 2005;114:992-95.
16. Cnattingius S, Galanti R, Grafström S, Hergens M-P, Lambe M, Nyrén O et al. Hälsorisker med svenskt snus. Stockholm: Statens Folkhälsoinstitut, 2005.
17. Teo KK, Ounpuu S, Hawken S et al. Tobacco use and risk of myocardial infarction in 52 countries in the INTERHEART study: A case-control study. Lancet 2006;368:647-58.
18. Norberg M, Stenlund H, Lindahl B, Boman K, Weinehall L. Contribution of Swedish moist snuff to the metabolic syndrome: A wolf in sheep's clothing? Scand J Public Health 2006;34:576-83.
19. Gupta PC, Sreevidya S. Smokeless tobacco use, birth weight, and gestational age: Population based, prospective cohort study of 1217 women in Mumbai, India. BMJ 2004;328:1538.
20. Steyn K, de Wet T, Saloojee Y, Nel H, Yach D. The influence of maternal cigarette smoking, snuff use and passive smoking on pregnancy outcomes: the Birth To Ten Study. Paediatr Perinat Epidemiol 2006;20 90-99.
21. Broadstock M. Systematic review of the health effects of modified smokeless tobacco products. Christchurch: New Zealand Health Technology Assessment, 2007:10:1-129.
22. Critchley JA, Unal B. Health effects associated with smokeless tobacco: a systematic review. Thorax 2003;58:435-43.
23. Gilljam H, Galanti MR. Role of snus (oral moist snuff) in smoking cessation and smoking reduction in Sweden. Addiction 2003;98 1183-89.
24. Tomar SL, Connolly GN, Wilkenfeld J, Hermingfield JE. Declining smoking in Sweden: Is Swedish Match getting the credit for Swedish tobacco control's efforts? Tob Control 2003;12:368-71.
25. Furberg H, Bulik CM, Lerman C, Lichtenstein P, Pedersen NL. Sullivan PF. Is Swedish snus associated with smoking initiation or smoking cessation? Tob Control 2005;14:422-24.
26. U.S. Department of Health and Human Services. Preventing Tobacco Use Among Young People: A Report of the Surgeon General. Atlanta, GA: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 1994.
27. Galanti MR, Rosendahl I, Post A, Gilljam H. Early gender differences in adolescent tobacco use - the experience of a Swedish cohort. Scand J Public Health 2001;29:314-17.
28. Silagy C, Lancaster T, Stead L, Mant D, Fowler G. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2004,CD000146.
29. Federal Trade Commission. Smokeless Tobacco Report for the Years 2000 and 2001. Washington DC: Federal Trade Commission, 2003.
30. Gray N. Mixed feelings on snus. Lancet 2005;366:966-67.